Mazdutide (IBI362) is a synthetic long-acting peptide dual agonist targeting both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR). Developed as a once-weekly research compound, it incorporates structural modifications enabling stable albumin binding for extended plasma half-life. Its dual receptor engagement profile distinguishes it from pure GLP-1 receptor agonists by adding direct glucagon receptor activity.
Researchers have studied Mazdutide for its combined metabolic effects through simultaneous GLP-1R and GCGR activation. GLP-1R agonism in research contexts is associated with augmented insulin secretion, gastric emptying delay, and central appetite suppression. GCGR agonism is thought to increase energy expenditure and stimulate hepatic fatty acid oxidation. Research has explored whether these mechanisms act synergistically or complementarily in preclinical metabolic models.
Preclinical studies in rodent obesity models have examined Mazdutide’s effects on body weight, fat mass, liver lipid content, and glycemic parameters. Clinical research programs have explored its cardiometabolic effects. Researchers have specifically examined the balance between GLP-1R and GCGR engagement in optimizing metabolic outcomes while managing potential effects on blood glucose. Its dual mechanism makes it a valuable tool for studying the coordinated biology of the incretin and glucagon axes.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
